this study, we extended the analysis of the activities of the bis-imidazolinylindole class of antibacterials against two clinically important antibiotic-resistant pathogens.
As our previous studies demonstrated that the bis-imidazolinylindole compounds MBX 1066, MBX 1090, MBX 1113 and MBX 1128 (see Table 1 for the structures) are active against M. smegmatis, 4 we investigated their effect on one susceptible (H37Rv) and seven multidrug-resistant isolates of M. tuberculosis. Table 1 summarizes the in vitro activities of the four compounds. MICs ranged from o0.02 to 1.3 mg ml À1 . The compounds MBX 1066 and MBX 1113 exhibited more potent antimycobacterial activity than did MBX 1090 and MBX 1128. Next, the antimycobacterial activity of MBX 1066 was compared with its structural analog, MBX 1162 (see Table 2 for the structure), which has previously shown to exhibit potent activity against Gram-positive and Gram-negative bacteria. 6 As shown in Table 2 , MBX 1162 was highly active against all the multidrugresistant isolates of M. tuberculosis and compared favorably with MBX 1066. MBX 1162 was assayed for cytotoxicity against HeLa cells as described previously 4 and exhibited slightly increased toxicity (CC 50 ¼ 4 mg ml À1 ) compared with its parent MBX 1066 (CC 50 ¼ 33 mg ml À1 ). 4 Previously, we reported that the four bis-imidazolinylindole compounds examined herein are quite active in vitro against MRSA, with MIC values ranging from 0.2 to 5 mg ml À1 . 4 To investigate the in vivo efficacy of these compounds, ICR/Swiss Webster mice (n ¼ 10) were challenged via the i.p. route with S. aureus strain NRS384, a community-associated methicillin-resistant (cMRSA) clinical isolate. One hour post infection, mice were treated via the i.v. route with a single dose of compound MBX 1066 (1 or 10 mg kg À1 ), MBX 1090 (1 or 10 mg kg À1 ) or MBX 1162
(1 or 10 mg kg À1 ). A 70-100% survival rate was observed in the compound-treated mice ( Table 3 ). The protective effects were similar to those observed with the reference antibiotic daptomycin. Furthermore, sampling of the spleen for bacterial load revealed a 2-4 log reduction in CFU (per tissue) in each of the groups compared with the untreated control (Table 3) . Thus, the compounds are active in vivo against cMRSA infection.
In summary, we have shown that several members of the bisimidazolinylindole compounds exhibit very potent in vitro activity against both susceptible and multidrug-resistant isolates of M. tuberculosis as well as in vivo activity against cMRSA. A newer analog, MBX 1162, demonstrated equivalent potency and slightly increased mammalian cell toxicity compared with MBX 1066. Optimization of the scaffold proceeds with the goal of lessening toxicity while Antibacterial activity against antibiotic-resistant strains RG Panchal et al maintaining potency. These compounds represent a promising new scaffold for the treatment of drug-resistant bacterial pathogens.
EXPERIMENTAL PROCEDURE Bacterial strains
The M. tuberculosis clinical isolates tested in this study are maintained at an inhouse repository at the Southern Research Institute (Table 1 ) and the National Institute of Allergy and Infectious diseases 7 ( Table 2 ). The drug resistance profiles for each clinical isolate are listed in their respective tables. S. aureus NRS384, a cMRSA clinical isolate representative of the USA300 clone, was used in the in vivo efficacy studies. The isolate is both staphylococcal chromosomal cassette mec type IV positive and Panton-Valentine leucocidin positive. The isolate was obtained from the Network on Antimicrobial Resistance in S. aureus (NARSA, Herndon, VA, USA).
In vitro growth inhibition studies MIC was determined using the broth microdilution method. 8 Briefly, compounds were dissolved in dimethyl sulfoxide and then diluted with Middlebrook 7H9 broth (BD, Sparks, MD, USA). Twofold serially diluted compounds (0.1 ml per well) were added to 96-well microtiter plates. The plates were inoculated with appropriate bacterial cultures that were standardized turbidimetrically to a concentration of 5 Â 10 5 per well. The plates were incubated at 37 1C for 7 days. MIC was determined visually as the lowest amount of drug that completely inhibited growth and was scored by comparing the growth in each well with growth in the negative-control wells (bacteria only) and positive-control wells (isoniazid).
In vivo efficacy in the mouse model of methicillin-resistant S. aureus infection
Female ICR/Swiss mice (Charles River Laboratories, Wilmington, MA, USA) were challenged i.p. with 7.4 Â 10 7 CFU of cMRSA. After 1 h, mice were treated via i.v. route with 1 or 10 mg kg À1 of compounds. On day 2, mice that survived challenge were euthanized and spleen harvested. Homogenized spleen was serially diluted in sterile phosphatase-buffered saline and appropriate concentrations plated on Trypticase Soy Agar plates. The number of CFU per tissue was determined by quantitative colony counts.
